日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial

Depatuxizumab mafodotin治疗EGFR扩增型新诊断胶质母细胞瘤:一项III期随机临床试验

Lassman, Andrew B; Pugh, Stephanie L; Wang, Tony J C; Aldape, Kenneth; Gan, Hui K; Preusser, Matthias; Vogelbaum, Michael A; Sulman, Erik P; Won, Minhee; Zhang, Peixin; Moazami, Golnaz; Macsai, Marian S; Gilbert, Mark R; Bain, Earle E; Blot, Vincent; Ansell, Peter J; Samanta, Suvajit; Kundu, Madan G; Armstrong, Terri S; Wefel, Jeffrey S; Seidel, Clemens; de Vos, Filip Y; Hsu, Sigmund; Cardona, Andrés F; Lombardi, Giuseppe; Bentsion, Dmitry; Peterson, Richard A; Gedye, Craig; Bourg, Véronique; Wick, Antje; Curran, Walter J; Mehta, Minesh P

The SARS-CoV-2 Virus and the Cholinergic System: Spike Protein Interaction with Human Nicotinic Acetylcholine Receptors and the Nicotinic Agonist Varenicline.

SARS-CoV-2 病毒与胆碱能系统:刺突蛋白与人类尼古丁乙酰胆碱受体和尼古丁激动剂伐尼克兰的相互作用

Carlson Eric C, Macsai Marian, Bertrand Sonia, Bertrand Daniel, Nau Jeffrey

A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin

一项针对接受 Depatuxizumab Mafodotin 治疗的表皮生长因子受体扩增型胶质母细胞瘤患者的眼部副作用管理的 3b 期研究

Vize, Colin J; Kim, Stella K; Matthews, Tim; Macsai, Marian; Merrell, Ryan; Hsu, Sigmund; Kundu, Madan Gopal; Yoon, Jennifer; Kennedy, Emma; Pai, Madhavi; Bain, Earle; Lassman, Andrew B; Moazami, Golnaz

Does Dry Eye Disease Severity Impact Efficacy of Varenicline Solution Nasal Spray on Sign and Symptom Treatment Outcomes?

干眼症的严重程度是否会影响伐尼克兰溶液鼻喷雾剂对体征和症状治疗效果的影响?

Sheppard, John D; O'Dell, Leslie E; Karpecki, Paul M; Raizman, Michael B; Whitley, Walter O; Blemker, Gretchen; Hemphill, Mandy; Hendrix, Laura H; Gibson, Andrea; Macsai, Marian

OC-01 (Varenicline Solution) Nasal Spray for the Treatment of Dry Eye Disease Signs and Symptoms in Subjects with Autoimmune Disease: Integrated Data from ONSET-1 and ONSET-2

OC-01(伐尼克兰溶液)鼻喷雾剂治疗自身免疫性疾病患者的干眼症体征和症状:来自 ONSET-1 和 ONSET-2 的综合数据

Schallhorn, Julie M; McGee, Selina; Nau, Jeffrey; Macsai, Marian; Gibson, Andrea; Blemker, Gretchen; Hendrix, Laura H; Massaro-Giordano, Mina

Matching-adjusted indirect comparison of phase 3 clinical trial outcomes of OC-01 (varenicline solution) nasal spray and lifitegrast 5% ophthalmic solution for the treatment of dry eye disease

OC-01(伐尼克兰溶液)鼻喷雾剂和利非格司特5%滴眼液治疗干眼症的3期临床试验结果的匹配调整间接比较

White, Darrell E; Hendrix, Laura H; Sun, Lucille; Tam, Iris; Macsai, Marian; Gibson, Andrea A

OC-01 (Varenicline Solution) Nasal Spray Demonstrates Consistency of Effect Regardless of Age, Race, Ethnicity, and Artificial Tear Use

OC-01(伐尼克兰溶液)鼻喷雾剂疗效稳定,不受年龄、种族、民族和人工泪液使用情况的影响。

Epitropoulos, Alice T; Daya, Sheraz M; Matossian, Cynthia; Kabat, Alan G; Blemker, Gretchen; Striffler, Kristen; Hendrix, Laura; Macsai, Marian; Gibson, Andrea

Matching-adjusted indirect comparison of phase 3 clinical trial outcomes: OC-01 (varenicline solution) nasal spray and cyclosporine a 0.05% ophthalmic emulsion for the treatment of dry eye disease

匹配调整的间接比较3期临床试验结果:OC-01(伐尼克兰溶液)鼻喷雾剂和0.05%环孢素眼用乳剂治疗干眼症

Visco, Denise M; Hendrix, Laura H; Sun, Lucille; Tam, Iris; Macsai, Marian; Gibson, Andrea A

Application of BisANS fluorescent dye for developing a novel protein assay

BisANS荧光染料在新型蛋白质检测方法开发中的应用

Datki, Zsolt; Olah, Zita; Macsai, Lilla; Pakaski, Magdolna; Galik, Bence; Mihaly, Gabor; Kalman, Janos

Exceptional in vivo catabolism of neurodegeneration-related aggregates

神经退行性相关聚集体的体内分解代谢异常

Zsolt Datki, Zita Olah, Tibor Hortobagyi, Lilla Macsai, Katalin Zsuga, Livia Fulop, Zsolt Bozso, Bence Galik, Eva Acs, Angela Foldi, Amanda Szarvas, Janos Kalman